Trivium Point Advisory LLC Buys 10,440 Shares of Medtronic PLC $MDT

Trivium Point Advisory LLC grew its stake in shares of Medtronic PLC (NYSE:MDT) by 20.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,877 shares of the medical technology company’s stock after purchasing an additional 10,440 shares during the quarter. Trivium Point Advisory LLC’s holdings in Medtronic were worth $5,848,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in MDT. Curbstone Financial Management Corp grew its position in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after acquiring an additional 100 shares during the period. Baker Tilly Wealth Management LLC raised its holdings in shares of Medtronic by 3.3% in the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after purchasing an additional 102 shares during the period. Riverbend Wealth Management LLC lifted its stake in Medtronic by 3.2% in the 3rd quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after purchasing an additional 107 shares during the last quarter. Maseco LLP grew its holdings in Medtronic by 32.1% during the fourth quarter. Maseco LLP now owns 444 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 108 shares during the period. Finally, Holistic Financial Partners increased its position in Medtronic by 3.0% during the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock worth $352,000 after buying an additional 109 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the subject of a number of recent analyst reports. Piper Sandler cut their price objective on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research report on Wednesday, April 1st. Leerink Partners restated an “outperform” rating and issued a $119.00 price target on shares of Medtronic in a research note on Tuesday, March 10th. Citigroup cut their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Truist Financial decreased their price objective on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.25.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Trading Down 1.7%

MDT stock opened at $85.66 on Friday. Medtronic PLC has a 52 week low of $79.93 and a 52 week high of $106.33. The company has a market capitalization of $109.98 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.26 and a beta of 0.75. The company’s 50-day simple moving average is $91.85 and its 200 day simple moving average is $95.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio is presently 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).